AU6702596A - Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases - Google Patents

Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Info

Publication number
AU6702596A
AU6702596A AU67025/96A AU6702596A AU6702596A AU 6702596 A AU6702596 A AU 6702596A AU 67025/96 A AU67025/96 A AU 67025/96A AU 6702596 A AU6702596 A AU 6702596A AU 6702596 A AU6702596 A AU 6702596A
Authority
AU
Australia
Prior art keywords
medicament
manufacture
treatment
pde inhibitors
bladder diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67025/96A
Other languages
English (en)
Inventor
Wolf-Georg Forssmann
Udo Jonas
Christian Georg Stief
Michael Carsten Truss
Stefan Uckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HORST DIETER KUMMER
Original Assignee
HORST DIETER KUMMER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HORST DIETER KUMMER filed Critical HORST DIETER KUMMER
Publication of AU6702596A publication Critical patent/AU6702596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU67025/96A 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases Abandoned AU6702596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19529102A DE19529102A1 (de) 1995-08-08 1995-08-08 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
DE19529102 1995-08-08
PCT/EP1996/003393 WO1997005876A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Publications (1)

Publication Number Publication Date
AU6702596A true AU6702596A (en) 1997-03-05

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67025/96A Abandoned AU6702596A (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Country Status (9)

Country Link
EP (1) EP0843553A1 (de)
JP (1) JP2000501698A (de)
AU (1) AU6702596A (de)
CA (1) CA2228314A1 (de)
DE (1) DE19529102A1 (de)
EA (1) EA199800192A1 (de)
HU (1) HUP0104619A3 (de)
WO (1) WO1997005876A1 (de)
ZA (1) ZA966698B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one

Also Published As

Publication number Publication date
CA2228314A1 (en) 1997-02-20
DE19529102A1 (de) 1997-02-13
JP2000501698A (ja) 2000-02-15
ZA966698B (en) 1998-02-09
EP0843553A1 (de) 1998-05-27
EA199800192A1 (ru) 1999-06-24
HUP0104619A2 (hu) 2002-04-29
WO1997005876A1 (en) 1997-02-20
HUP0104619A3 (en) 2002-06-28

Similar Documents

Publication Publication Date Title
IL174732A0 (en) Use of crystal modification of a n-phenyl-2-pyrimidineamine derivative in the preparation of a medicament for the treatment of restenosis
HK1009939A1 (en) Medicament for treating cardiac inflammatory diseases
AU7005694A (en) Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
EP1029540A3 (de) Verwendung von Droloxifen zur Behandlung von cardiovaskulären Erkrankungen
AU7578696A (en) Morpholine derivatives and their use as therapeutic agents
AU5384096A (en) Use of vitamin D2 or vitamin D4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
IL119894A (en) Use of thiazolidine in the preparation of a medicament for the treatment of osteoporosis
AU4477893A (en) Use of C1-inactivator for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
EP0765663A3 (de) Verwendung von Dienogest zur Herstellung eines Arzneimittels zur Behandlung der Haut mittels topischer Anwendung
AU7269294A (en) Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours
AU8038998A (en) Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
AU7042796A (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
HK1001375A1 (en) Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
EP0765661A3 (de) Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung von Glomerulonephritis
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
EP0740936A3 (de) Verwendung von Benzopyranderivaten zur Herstellung von Arzneimitteln zur Behandlung der mit dem natrium-unabhängig Cl-/HCO3- Austauscher verbundenen Krankheiten
HUP9801686A3 (en) Use of aminotetralin derivative for producing pharmaceutical for the therapy of cardiovascular diseases
AU6702596A (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
AU3263795A (en) Medicament for treatment or prophylaxis of incontinence
IL115505A (en) Use of inhibitors of cyclooxygenase in the preparation of medicaments for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted